Microbot Medical Inc. (MBOT) · Oct 20, 2026 · Other events
Patent portfolio expanded — 44 issued patents; 49 pending applications
Microbot Medical announced new patent approvals across four countries, expanding LIBERTY’s protection as U.S. commercialization advances and CE Mark work continues.
Microbot Medical is transitioning LIBERTY from an FDA-cleared device into a commercial-stage product: it began limited U.S. commercialization in late 2025, moved to a full market release in April 2026, and has started recording early revenue while building toward international expansion.
The filing adds a real but indirect asset: broader patent protection. Microbot announced several new approvals in the U.S., Japan, China, and Canada, bringing its portfolio to 44 issued patents and 49 pending applications. 〔0〕 That improves the company’s ability to defend and potentially monetize LIBERTY as adoption expands, but it does not itself demonstrate more procedures, customers, revenue, or regulatory clearance.
This is modestly better than the pre-filing story, but not a commercial inflection point. The international direction was already established: Microbot is pursuing CE Mark certification after securing its first non-U.S. marketing clearance in Israel and signing an exclusive Israeli distribution agreement earlier in October. The new information is the additional patent coverage and the larger stated portfolio, not a change in strategy or an acceleration of sales.
The filing’s strongest limitation is what it does not say. It provides no patent-by-patent economic value, no added customer or utilization data, no revenue update, and no CE Mark approval. The company says the patents support “future market expansion and monetizing” its technology, but that remains an opportunity rather than an outcome. 〔1〕
Bottom line: The announcement strengthens Microbot’s long-term competitive defenses around LIBERTY and is mildly incremental to the story. It matters strategically, but it does not materially change the near-term commercialization proof points investors still need.
CE Mark decision, expected by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!